C

Corcept Therapeutics
D

CORT

35.110
USD
-0.84
(-2.34%)
مفتوح الان
حجم التداول
19,756
الربح لكل سهم
0
العائد الربحي
-
P/E
43
حجم السوق
3,737,983,063
أصول ذات صلة المقالات

العنوان: Corcept Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.